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A B S T R A C T
Breast cancer is amongst the most common forms of cancer, is predominantly a woman’s illness, and is the most frequently reported invasive cancer in women
worldwide (Bray et al., 2018). Varying risk factors have been identified, including genetics, family history, lifestyle, age and the use of hormone replacement therapy.
Mastitis, also predominantly a woman’s illness, is an inflammatory condition of the breast that, despite being an inflammation-related condition, is not currently
considered a risk factor for breast cancer. This appears counterintuitive as epidemiological studies have identified chronic inflammation as a contributor to cancer
risk, for example in gastric, oesophageal and colon cancers (Lin et al., 2016; Qadri et al., 2014; Principe et al., 2017). Previous reports have focused on women
hospitalised for mastitis, and most commonly on puerperal mastitis, perhaps underestimating the relationship between breast cancer and non-lactational mastitis.
Our hypothesis, based on systematic review, suggests that a longitudinal study of this disease, affecting women predominantly, is warranted.
Background to the hypothesis
Breast cancer is amongst the most common forms of cancer, is
predominantly a woman’s illness, and is the most frequently reported
invasive cancer in women worldwide [1]. Varying risk factors have
been identified, including genetics, family history, lifestyle, age and the
use of hormone replacement therapy. Mastitis, also predominantly a
woman’s illness, is an inflammatory condition of the breast that can be
caused by milk stasis or infection. It can also occur in non-lactational
settings. However, despite mastitis being an inflammation-related
condition, it is not currently considered a risk factor for breast cancer.
This appears counterintuitive as epidemiological studies have identified
chronic inflammation as a contributor to cancer risk, for example in
gastric, oesophageal and colon cancers [2–4].
More specifically, the two main forms of mastitis are puerperal and
non-puerperal, with the primary distinction related to whether or not
mastitis occurs in a lactational setting. Puerperal mastitis, also referred
to as lactation mastitis, is the more common, and is a result of milk
stasis or infection occurring in women who have recently given birth
and are, most likely, breast-feeding [5]. Milk stasis results typically
from inefficient removal of milk from the breast causing breast in-
flammation and pain [6]. Unfortunately, milk stasis promotes devel-
opment of an environment favourable to bacterial growth and infection.
Additionally, in non-puerperal mastitis, also termed non-lactational
mastitis, certain bacterial species may penetrate the breast causing
infection. The bacterial species most associated with both forms of
mastitis is coagulase positive Staphylococcus aureus [8], commonly
found on the skin and in breast milk. Symptoms of mastitis are most
often alleviated with removal of milk and/or the administration of
antimicrobials [6]. Both forms of mastitis result in inflammation and
both have the potential for manifest bacterial growth. A better under-
standing of the systemic effects on breast tissue is needed to elucidate
any long-term effects resulting from the condition.
Given the known associations between inflammation and develop-
ment of cancer, it appears rational to evaluate the potential relationship
between mastitis-related inflammation and breast cancer, and it is
surprising perhaps that this has not been done prior to this study.
However, mitigating factors include a paucity of data published on the
topic. We conducted a PRISMA-compliant systematic review using
PubMed, Web of science, Cochrane and EMBASE databases
(1990–2019). The following terms were used to identify articles:
“mastitis” and “breast cancer” and “risk”. Papers describing retro-
spective or prospective cohort studies that discussed incidence of breast
cancer diagnosis in patients formerly diagnosed with mastitis were se-
lected to determine the risk of breast cancer following development of
mastitis. Additionally, appraisal included retrospective and prospective
cohort studies of patients with a history of breast cancer and reporting
subsequent diagnosis of mastitis.
The search yielded 318 unique articles. Notably, no studies were
found that discussed mastitis rates in women with a history of breast
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cancer. Therefore, in-depth appraisal related to patients diagnosed with
mastitis and diagnosed subsequently with breast cancer. It is worth
noting that the amount of research focusing on this issue is meagre.
However, four papers were identified that reported data relevant to the
possibility of an association between mastitis and breast cancer [7–10].
All four studies referred to elevated incidence of breast cancer among
women diagnosed with mastitis in comparison to women who had
never been diagnosed with the disease.
In particular, Peters et al (Germany) [7] and Lambe et al (Sweden)
[8] performed large population based studies, albeit that their focus
was on different types of mastitis. Peters et al targeted non-lactational /
nonpuerperal mastitis while the patient cohort in the Lambe et al study
comprising puerperal mastitis patients predominantly (97%). None-
theless, both studies detailed an increased incidence of breast cancer
(1.8% and 1.23%, respectively). In particular, Peters and his colleagues
[7] declared a “tentative” 37 fold increase in risk of cancer diagnosis
within 12 months of treatment for women with nonpuerperal mastitis
that had been diagnosed through clinical presentation, laboratory
analysis or sonography. Although the increased risk was calculated
using an age related standardised ratio the number of subjects diag-
nosed subsequently with breast cancer was relatively small, and the
authors declared a bias. Specifically, in three of the five cases, non-
palpable breast tumours were detected only by mammography. Indeed,
the subjects of the Peters et al. study were screened for breast cancer
twice within 12 months. The authors were open in saying that had they
only done “one mammogram directly after healing“ of the mastitis in-
flammation they would have missed those three cases [7].
Lambe et al. [8] performed an in-depth analysis of a larger cohort of
Swedish women, reporting a modest increased risk of breast cancer
incidence following mastitis. The study, however, was limited in its
scope in that inclusion required hospitalisation (i.e., acute illness), and
exclusion criteria involved: prior multiple births; prior diagnosis of
mastitis or a diagnosis more than 12 months previously. The study,
therefore, emphasised involvement of mastitis in a cohort of women
that is narrower than the general population, and entertained only the
possibility of mastitis involvement if occurrence was within one year of
entry into the study. The reported incidence rate ratio was 1.23 (95%
confidence interval = 1.02–1.49). Furthermore, confidence intervals
pertaining to the laterality of mastitis and breast cancer ranged from
41% to 62%. Although a weak correlation exists, it is worth noting that
data on laterality existed for only 87 of the total 106 women. While
there are scientific and clinical rationales for the inclusion and exclu-
sion criteria above, it seems reasonable to suggest that a more inclusive
study population may have indicated greater association.
In contrast, the emphasis of the Ghadiri et al. study (Iran) [9] was
quite narrow; specifically lactation discontinuation and affect on sub-
sequent breast health. The reported data did not differentiate between
breast abscesses and other benign diseases, no data were reported for
mastitis patients independently, and hormone use (for HRT) was a
confounder that was not appropriately dealt with. However, in short,
the authors stated that those subjects who discontinued lactation fol-
lowing a diagnosis of mastitis had an increased rate of breast cancer
compared with those who discontinued for other reasons. An increased
rate of breast cancer was also reported in women who ceased lactation
due to an intervening benign breast disease (odds ratio 3.669).
Most recently, in 2019 Chang et al. (Taiwan) [10] described a large
study comparing incidence of breast cancer in women who experienced
non-lactational mastitis as opposed to those who did not. Unlike the
Peters et al. study [7], the comprehensive statistical approach used in
Taiwan accounted for potential confounders such as socioeconomic
demographics, hormonal medications and comorbidities that have
known risk elevating association with breast cancer, such as hy-
pertension, chronic obstructive pulmonary disease, thyroid disease,
diabetes, hyperlipidemia and obesity. Crucially, four control women
were matched to each woman with non-lactational mastitis. However,
smoking and diet, family history and parity status were not considered,
as such data were not accessible. Their outcome was a significant as-
sociation between non-lactational mastitis and subsequent breast
cancer. More precisely, compared with women in the comparison
group, women who had non-lactational mastitis before the age of
40 years (aHR = 2.22, 95% CI: 1.18–4.18) and at the age of 40 to
49 years of age (aHR = 2.00, 95% CI: 1.11–4.04) had a significantly
higher risk of breast cancer. However, women with lactational mastitis
did not exhibit a statistically significant risk of developing breast
cancer, relative to women in the comparison group. Furthermore, risk
of breast cancer in women increased significantly as the number of non-
lactational mastitis occurrences increased.
Statement of hypothesis
Our hypothesis, therefore, relates to the relationship between mas-
titis and breast cancer that has not been recognised broadly. Indeed, it
is clear from the four significant studies described above that the as-
sociation between mastitis, the more common puerperal form and the
more infrequent non-lactational form, has been underestimated. The
reasons for this relate largely to study inclusion criteria that have ef-
fectively narrowed relevance of the study outcomes to general popu-
lations, and interpretation of these outcomes to reduce the perceived
risk of mastitis in the context of prior incidence of mastitis.
Mechanistically, the rationale for increased risk of breast cancer due
to prior puerperal mastitis relates to bacterial infection and establish-
ment of a promalignant environment. The role that bacteria play in
development of cancers is now widely accepted [11]. There is in-
creasing acceptance of the role of our microbiome in cancer develop-
ment. The breast microbiome is distinctly diverse between benign and
malignant diseases of the breast [12,13]. Indeed, there is evidence that
a precancerous environment may actually be favourable to bacteria. For
example, hypoxia is a common characteristic of oncogenesis and has
been shown to increase cytotoxin production and biofilm formation of
Staphylococcus aureus [14]. Furthermore, malignant cells maintain their
intracellular pH level through an acid extrusion process [15] resulting
in environmental acidification [16]. S. aureus achieves optimum growth
between pH 6 and 7, provided for in breast malignancy with associated
environmental pH ranges of between 6.5 and 6.7 [16].
The consequence of mastitis-related bacterial proliferation is in-
flammation, recognised as an initiator for cancer [17,18]. There are two
primary outcomes relevant to cancer development.
Firstly, recruitment of phagocytes to an area of infection results in
the secretion of proinflammatory cytokines and adipokines. These, in
turn, attract more immune system cells and elevate the inflammatory
response. This mediates intracellular signalling, which can induce
pathways that activate oncogenic mutations and transcription of pro-
teins involved in the initiation and promotion of cancers [18]. Some
cytokines and adipokines controversially associated with breast cancer
include leptin, interlukin-6 (IL6), adiponectin and Tumour Necrosis
Factor-α (TNF-α). The latter association is debated consistently due to
contradicting literature. However, the ability of TNF-α to activate NF-
ĸB, promoting cell cycle and cell proliferation and its ability to stimu-
late estrogen synthesis contributes to its cancer promoting reputation
[18]. More certain is IL6 as an activator of the Janus kinase pathway.
This pathway is involved in initiating the transcription of a well known
oncogene MYC and other inflammatory cytokines such as IL8. This
promotes a reciprocal feedback loop to manipulate an environment
favourable to oncogenesis [18].
Separately, the rationale for increased risk of breast cancer due to
prior non-puerperal, non-lactational mastitis relates to damage of the
extracellular matrix (ECM) of the breast (caused potentially by mastitis
at a young age) and could be a significant contributor to breast cancer
development. A multifaceted network of proteins and glycoproteins
that is required to maintain tissue homeostasis, the ECM is crucial in
regulating cellular behaviour [19]. Mastitis and associated inflamma-
tion during a time of development could result in dysregulation that
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leaves a woman more susceptible to breast cancer [20]. Mastitis-asso-
ciated immune cascade may promote hormonal imbalances and greater
risk of breast cancer [21].
Testing the hypothesis
Certainly, this hypothesis is limited by the availability of literature
on this subject. However, the large population based cohorts described
here strengthen the argument that mastitis could reasonably be pro-
posed to increase the risk of breast cancer. Crucially, mastitis is a
possible risk that can potentially be mitigated in contrast to other breast
cancer risk factors, for example, family history and aging. The most
common form of the disorder, puerperal mastitis, occurs at a time when
women are in regular contact with medical practitioners and the use of
preventative measures (e.g., ensuring sufficient milk flow) could reduce
a woman’s likelihood of developing mastitis. It seems evident that
large-scale, prospective longitudinal studies are warranted in-
vestigating puerperal and non-puerperal mastitis. Prospective studies
focused on both forms of the disease may discern any mechanistic
differences between them, and the effect these may have on breast
cancer risk. Such studies should involve broad age groups, take into
consideration potential confounders including lifestyle factors (e.g.,
diet, smoking, alcohol & substance abuse, socioeconomic demo-
graphics, history of childbirth, comorbidities, medicines intake, etc),
surveillance and screening of women immediately following diagnosis
of mastitis and continuing with multiple mammograms for at least
12 months following alleviation of symptoms or resolution of mastitis;
and (where feasible and ethically appropriate) collection of biopsy
specimens for correlation of biomarkers at time of surgery, if required.
Such a suitably-powered and resourced investigation would present
an opportunity to more clearly understand this aspect of women’s
health and reduce risk of this potentially lethal disease.
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